Vertex Pharmaceuticals Inc
VRTX447.380USD
-2.140-0.48%
Handelsschluss 12/18, 16:00（ET）Kurse um 15 Minuten verzögert
113.61BMarktkapitalisierung
31.27KGV TTM
mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Informationen
BörsenkürzelVRTX
Name des UnternehmensVertex Pharmaceuticals Inc
IPO-datumJul 24, 1991
CEOKewalramani (Reshma)
Anzahl der mitarbeiter6100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 24
Addresse50 Northern Avenue
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02210
Telefon16173416393
Websitehttps://www.vrtx.com/
BörsenkürzelVRTX
IPO-datumJul 24, 1991
CEOKewalramani (Reshma)
Führungskräfte von Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.31K
-2.22%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-11.24%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.83B
62.08%
Europe
910.90M
30.94%
Other
205.60M
6.98%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Andere
63.49%
Aktionäre
Aktionäre
Anteil
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Andere
63.49%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
60.06%
Investment Advisor/Hedge Fund
28.01%
Research Firm
2.35%
Pension Fund
2.27%
Bank and Trust
2.08%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.14%
Insurance Company
0.09%
Andere
2.36%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
28.73M
11.21%
+198.84K
+0.70%
Jun 30, 2025
The Vanguard Group, Inc.
23.86M
9.31%
+479.23K
+2.05%
Jun 30, 2025
Capital Research Global Investors
16.11M
6.28%
+1.57M
+10.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
14.15M
5.52%
+156.31K
+1.12%
Jun 30, 2025
State Street Investment Management (US)
11.78M
4.59%
-13.43K
-0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.93M
2.31%
+166.99K
+2.90%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
5.26M
2.05%
-18.59K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
4.81M
1.88%
-641.36K
-11.76%
Jun 30, 2025
Capital International Investors
2.64M
1.03%
+1.99M
+305.59%
Jun 30, 2025
AllianceBernstein L.P.
4.38M
1.71%
+424.81K
+10.75%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Dec 5
Aktualisiert: Fri, Dec 5
Name
Anteil
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
Mehr Anzeigen
VanEck Biotech ETF
Anteil9.71%
ProShares Ultra Nasdaq Biotechnology
Anteil8.83%
Invesco Nasdaq Biotechnology ETF
Anteil8.76%
iShares Biotechnology ETF
Anteil7.43%
Invesco Biotechnology & Genome ETF
Anteil5.35%
Natixis Loomis Sayles Focused Growth ETF
Anteil4.48%
First Trust NASDAQ Pharmaceuticals ETF
Anteil4.23%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.5%
Franklin Genomic Advancements ETF
Anteil3.33%
Simplify Health Care ETF
Anteil3.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Vertex Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Vertex Pharmaceuticals Inc sind:
Capital World Investors hält 28.73M Aktien, was 11.21% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 23.86M Aktien, was 9.31% der Gesamtaktien entspricht.
Capital Research Global Investors hält 16.11M Aktien, was 6.28% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 14.15M Aktien, was 5.52% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 11.78M Aktien, was 4.59% der Gesamtaktien entspricht.
Capital World Investors hält 28.73M Aktien, was 11.21% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 23.86M Aktien, was 9.31% der Gesamtaktien entspricht.
Capital Research Global Investors hält 16.11M Aktien, was 6.28% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 14.15M Aktien, was 5.52% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 11.78M Aktien, was 4.59% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Vertex Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Vertex Pharmaceuticals Inc sind:
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Wie viele Institutionen halten Anteile an Vertex Pharmaceuticals Inc (VRTX)?
Mit Stand vom 2025Q3 halten 2933 Institutionen Anteile an Vertex Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 249.27M, was 98.24% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -0.32% gestiegen.
Was ist die größte Einnahmequelle von Vertex Pharmaceuticals Inc?
Am FY2025Q2 erzielte das Geschäft mit TRIKAFTA für Vertex Pharmaceuticals Inc den höchsten Umsatz in Höhe von 2.55B, was 86.65% des Gesamtumsatzes entspricht.
